These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32721992)

  • 41. Immunomodulaton and attenuation of lethal influenza A virus infection by oral administration with KIOM-C.
    Kim EH; Pascua PN; Song MS; Baek YH; Kwon HI; Park SJ; Lim GJ; Kim SM; Decano A; Lee KJ; Cho WK; Ma JY; Choi YK
    Antiviral Res; 2013 Jun; 98(3):386-93. PubMed ID: 23588232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.
    Wang B; Taylor J; Ratnamohan M; McPhie K; Kesson A; Dixit R; Booy R; Hurt A; Saksena N; Dwyer DE
    Euro Surveill; 2012 Jul; 17(27):. PubMed ID: 22790606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China.
    Huang W; Li X; Cheng Y; Tan M; Guo J; Wei H; Zhao X; Lan Y; Xiao N; Wang Z; Wang D; Shu Y
    Virol J; 2015 Jun; 12():96. PubMed ID: 26103966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016.
    Bragstad K; Hungnes O; Litleskare I; Nyrerød HC; Dorenberg DH; Hauge SH
    Influenza Other Respir Viruses; 2019 Jul; 13(4):372-381. PubMed ID: 30834715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oseltamivir-resistant seasonal A(H1N1) and A(H1N1)pdm09 influenza viruses from the 2007/2008 to 2012/2013 season in Nara Prefecture, Japan.
    Yoneda M; Okayama A; Kitahori Y
    Jpn J Infect Dis; 2014; 67(5):385-8. PubMed ID: 25241691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility.
    Paradis EG; Pinilla LT; Holder BP; Abed Y; Boivin G; Beauchemin CA
    PLoS One; 2015; 10(5):e0126115. PubMed ID: 25992792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
    Marathe BM; Mostafa HH; Vogel P; Pascua PNQ; Jones JC; Russell CJ; Webby RJ; Govorkova EA
    Antiviral Res; 2017 Dec; 148():20-31. PubMed ID: 29100887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance.
    Ottmann M; Duchamp MB; Casalegno JS; Frobert E; Moulès V; Ferraris O; Valette M; Escuret V; Lina B
    Antivir Ther; 2010; 15(5):721-6. PubMed ID: 20710053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards.
    Gillman A; Muradrasoli S; Söderström H; Holmberg F; Latorre-Margalef N; Tolf C; Waldenström J; Gunnarsson G; Olsen B; Järhult JD
    Appl Environ Microbiol; 2015 Apr; 81(7):2378-83. PubMed ID: 25616792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
    Pichon M; Gaymard A; Josset L; Valette M; Millat G; Lina B; Escuret V
    Antiviral Res; 2017 Sep; 145():160-167. PubMed ID: 28780426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid detection of the S247N neuraminidase mutation in influenza A(H1N1)pdm09 virus by one-step duplex RT-PCR assay.
    Takayama I; Nakauchi M; Fujisaki S; Odagiri T; Tashiro M; Kageyama T
    J Virol Methods; 2013 Mar; 188(1-2):73-5. PubMed ID: 23261798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus.
    Pokorná J; Pachl P; Karlukova E; Hejdánek J; Řezáčová P; Machara A; Hudlický J; Konvalinka J; Kožíšek M
    Viruses; 2018 Jun; 10(7):. PubMed ID: 29933553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
    Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
    Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity.
    Jin J; Chen Y; Wang D; Ma L; Guo M; Zhou C; Dou J
    Arch Pharm Res; 2018 Jun; 41(6):664-676. PubMed ID: 29572682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The epidemiology and spread of drug resistant human influenza viruses.
    Hurt AC
    Curr Opin Virol; 2014 Oct; 8():22-9. PubMed ID: 24866471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility.
    Farrukee R; Tai CM; Oh DY; Anderson DE; Gunalan V; Hibberd M; Lau GY; Barr IG; Messling VV; Maurer-Stroh S; Hurt AC
    PLoS Pathog; 2020 Jun; 16(6):e1008592. PubMed ID: 32555740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
    Kossyvakis A; Mentis AA; Tryfinopoulou K; Pogka V; Kalliaropoulos A; Antalis E; Lytras T; Meijer A; Tsiodras S; Karakitsos P; Mentis AF
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):361-371. PubMed ID: 27848039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
    Mifsud EJ; Tilmanis D; Oh DY; Ming-Kay Tai C; Rossignol JF; Hurt AC
    Antiviral Res; 2020 Apr; 176():104751. PubMed ID: 32088248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.